Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00752206 · ClinicalTrials.gov registry record · Phase 2
A Placebo-Controlled Study of Saracatinib (AZD0530) in Patients With Recurrent Osteosarcoma Localized to the Lung
A Phase 2 study, sponsored by Sarcoma Alliance for Research through Collaboration.
- Terminated
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
NCT00752206 is a Phase 2 study that was terminated before completion, run by Sarcoma Alliance for Research through Collaboration. The registered enrollment target is 38 participants.
The verdict
NCT00752206, a Phase 2 study, was terminated before completion, sponsored by Sarcoma Alliance for Research through Collaboration.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
Study Summary
The purpose of this study is to determine how long patients who undergo complete surgical removal of recurrent osteosarcoma in the lung will remain free of cancer after taking Saracatinib compared to patients taking placebo (a sugar pill).
Interventions
- DRUG Placebo
- DRUG Saracatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2009-03 |
| Est. Completion | 2017-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00752206
The ClinicalTrials.gov registry entry for NCT00752206 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sarcoma Alliance for Research through Collaboration, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00752206 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00752206 about?
NCT00752206 is a clinical study titled "A Placebo-Controlled Study of Saracatinib (AZD0530) in Patients With Recurrent Osteosarcoma Localized to the Lung". The purpose of this study is to determine how long patients who undergo complete surgical removal of recurrent osteosarcoma in the lung will remain free of cancer after taking Saracatinib compared to patients taking placebo (a sugar pill).
What is the current status of trial NCT00752206?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2009-03. Estimated completion is 2017-12.
What interventions are being tested in trial NCT00752206?
The interventions under investigation include: Placebo (DRUG), Saracatinib (DRUG).
Who is sponsoring clinical trial NCT00752206?
This trial is sponsored by Sarcoma Alliance for Research through Collaboration, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.